Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: A randomized, double-blind, placebo-controlled trial

International Journal of Geriatric Psychiatry

Volumn 29, Issue 9, 2014, Pages 978-986

  Alaka, Karla J ^a   Noble, William ^b   Montejo, Angel ^c,d   Dueñas, Héctor ^a   Munshi, Autar ^e   Strawn, Jeffrey R ^f   Lenox Smith, Alan ^a   Ahl, Jonna ^a   Bidzan, Leszek ^g   Dorn, Brita ^e   Ball, Susan ^a,h  

^a ELI LILLY AND COMPANY   (United States)

^b SYNEOS HEALTH   (United States)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^e Department of Psychiatry and Behavioral Neuroscience University of Cincinnati College of Medicine ^*

^f UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^g MEDICAL UNIVERSITY OF GDANSK   (Poland)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anxiety; duloxetine; functioning

Indexed keywords

DULOXETINE; PLACEBO; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; THIOPHENE DERIVATIVE;

ADVERSE OUTCOME; AGED; ARTICLE; CLINICAL ASSESSMENT; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; SHEEHAN DISABILITY SCALE; SOMNOLENCE; TREATMENT OUTCOME; VITAL SIGN; XEROSTOMIA; ANXIETY DISORDERS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DULOXETINE HYDROCHLORIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 84905856598     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4088     Document Type: Article

References (45)

1. Allgulander C, Nutt D, Detke M, et al,. 2008. A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol 22 (4): 417-425. (Pubitemid 351989976)
2. Allgulander C, Hackett D, Salinas E,. 2001. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 179: 15-22.
3. Allgulander C, Florea I, Huusom AK,. 2006. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 9 (5): 495-505. (Pubitemid 44607202)
4. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders (4th edn). American Psychiatric Association: Washington, DC.
5. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S,. 2012. An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World J Biol Psychiatry 13 (7): 510-516.
6. Bandelow B, Sher L, Bunevicius R, et al,. 2012. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16 (2): 77-84.
7. Byers AL, Yaffe K, Covinsky KE, Friedman MB, Bruce ML,. 2010. High occurrence of mood and anxiety disorders among older adults: The National Comorbidity Survey Replication. Arch Gen Psychiatry 67 (5): 489-496.
8. Cleeland CS, Ryan KM,. 1994. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23 (2): 129-138.
9. Davidson JR, Dupont RK, Hedges D, Haskins JT,. 1999. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60 (8): 528-535. (Pubitemid 29413473)
10. Davidson JR, Bose A, Korotzer A, Zheng H,. 2004. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 19 (4): 234-240. (Pubitemid 39014143)
11. Davidson J, Allgulander C, Pollack MH, et al,. 2008. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol 23 (6): 519-526.
12. Doyle AC, Pollack MH,. 2003. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry 64: 40-45. (Pubitemid 37464495)
13. Endicott J, Nee J, Harrison W, Blumenthal R,. 1993. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 29 (2): 321-326. (Pubitemid 23311543)
14. Folstein MF, Folstein SE, McHugh PR,. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (3): 189-198.
15. Gelenberg AJ, Lydiard RB, Rudolph R, et al,. 2000. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283 (23): 3082-3088. (Pubitemid 30399718)
16. Gonçalves DC, Byrne GJ,. 2012. Interventions for generalized anxiety disorder in older adults: systematic review and meta-analysis. J Anxiety Disord 26 (1): 1-11.
17. Guy W,. 1976. ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health (NIMH), Psychopharmacology Research Branch: Rockville, MD.
18. Hamilton M,. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32 (1): 50-55.
19. Hamilton M,. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
20. Hartford J, Kornstein S, Liebowitz M, et al,. 2007. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 22 (3): 167-174. (Pubitemid 46559873)
21. Hoffman EJ, Mathew SJ,. 2008. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med 75 (3): 248-262.
22. Katz IR, Reynolds CF 3rd, Alexopoulos GS, Hackett D,. 2002. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatric Soc 50 (1): 18-25. (Pubitemid 34053018)
23. Koponen H, Allgulander C, Erickson J, et al,. 2007. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 9 (2): 100-107. (Pubitemid 46607463)
24. Le Roux H, Gatz M, Wetherell JL,. 2005. Age at onset of generalized anxiety disorder in older adults. Am J Geriatr Psychiatry 13 (1): 23-30. (Pubitemid 41031112)
25. Lenze EJ, Rollman BL, Shear MK, et al,. 2009. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA 301 (3): 295-303.
26. Lipman RS,. 1982. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull 18 (4): 69-77. (Pubitemid 13223885)
27. Mackenzie CS, Reynolds K, Chou KL, Pagura J, Sareen J,. 2011. Prevalence and correlates of generalized anxiety disorder in a national sample of older adults. Am J Geriatr Psychiatry. 19 (4): 305-315.
28. Maier W, Philipp M,. 1985. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 18: 114-115. (Pubitemid 15137667)
29. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC,. 2006. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67 (5): 771-782. (Pubitemid 43946184)
30. Nicolini H, Bakish D, Duenas H, et al,. 2009. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 39 (2): 267-276.
31. Pollack MH, Zaninelli R, Goddard A, et al,. 2001. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62 (5): 350-357. (Pubitemid 32545557)
32. Posner K, Brown GK, Stanley B, et al,. 2011. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168 (12): 1266-1277.
33. Raskin A, Schulterbrandt J, Reatig N, McKeon JJ,. 1969. Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J Nerv Ment Dis 148 (1): 87-98.
34. Raskin J, Wiltse CG, Siegal A, et al,. 2007. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164 (6): 900-909. (Pubitemid 46972905)
35. Rickels K, Pollack MH, Sheehan DV, Haskins JT,. 2000. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157 (6): 968-974. (Pubitemid 30412349)
36. Rickels K, Zaninelli R, McCafferty J, et al,. 2003. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 160 (4): 749-756. (Pubitemid 41079609)
37. Robinson MJ, Oakes TM, Raskin J, et al,. 2014. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo. Am J Geriatr Psychiatry 22 (1): 34-45.
38. Rynn M, Russell J, Erickson J, et al,. 2008. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 25 (3): 182-189. (Pubitemid 351499896)
39. Shear MK, Vander Bilt J, Rucci P, et al,. 2001. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety 13 (4): 166-178. (Pubitemid 32550226)
40. Sheehan DV, Harnett-Sheehan K, Raj BA,. 1996. The measurement of disability. Int Clin Psychopharmacol 11 (Suppl 3): 89-95. (Pubitemid 26373761)
41. Sheehan DV, Lecrubier Y, Sheehan KH, et al,. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20): 22-33. (Pubitemid 29001829)
42. Stocchi F, Nordera G, Jonkinen RH, et al,. 2003. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 64 (3): 250-258. (Pubitemid 36457322)
43. Wittchen HU, Kessler RC, Beesdo K, et al,. 2002. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63 (Suppl 8): 24-34. (Pubitemid 34535254)
44. Wittchen HU, Jacobi F, Rehm J, et al,. 2011. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21 (9): 655-679.
45. Zigmond AS, Snaith RP,. 1983. The hospital anxiety and depression scale. Acta Psychiatr Scand 67 (6): 361-370. (Pubitemid 13098606)